Inactivated varicella zoster vaccine and herpes zoster

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/41040
• EU PAS number:
  EUPAS41039
• Study ID:
  41040
• Official title and acronym:
  Inactivated varicella zoster vaccine and herpes zoster
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Patients with a prescription for inactivated varicella zoster vaccine are compared to patients with a prescription for pneumococcal vaccine and patients with a prescription for live attenuated varicella zoster vaccine. Patients must have a minimum observation time of 180 days before and 28 days after the first prescription for the vaccine. Patients are followed for herpes zoster events during 28 days after the first prescription. Results are stratified by gender, age group, a history of varicella or herpes zoster, and a history of immunodeficiency or immunosuppression.
• Study status:
  Finalised

Research institutions and networks

Institutions

European Medicines Agency (EMA)

Study timelines

Date when funding contract was signed

Planned: 26/11/2019

Actual: 26/11/2019

Study start date

Planned: 08/01/2020

Actual: 08/01/2020

Data analysis start date

Planned: 08/01/2020

Actual: 08/01/2020

Date of final study report

Planned: 12/02/2020

Actual: 12/02/2020

Sources of funding

EMA

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable